SURMOUNT-2

Definition

The phase 3 trial of tirzepatide in adults with obesity AND type 2 diabetes. Garvey and colleagues (Lancet 2023) reported tirzepatide 15 mg producing -14.7% body weight reduction at 72 weeks versus placebo -3.2%, with HbA1c reductions exceeding most diabetes-specific GLP-1 trials. Supported FDA expansion of Zepbound labeling toward T2D-with-obesity populations.

SURMOUNT-2 trial deep-dive →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in trial

• SURMOUNT-5
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Looking for more depth?

• SURMOUNT-2 trial deep-dive
• Browse the full GLP-1 glossary (124 terms across 8 categories)
• Research articles — primary-source deep dives
• Tools and calculators
• Compare GLP-1 telehealth providers